359 related articles for article (PubMed ID: 33917885)
1. From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct.
González-Gascón-Y-Marín I; Muñoz-Novas C; Rodríguez-Vicente AE; Quijada-Álamo M; Hernández-Sánchez M; Pérez-Carretero C; Ramos-Ascanio V; Hernández-Rivas JÁ
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917885
[TBL] [Abstract][Full Text] [Related]
2. Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia.
Yun X; Zhang Y; Wang X
Biomark Res; 2020; 8():40. PubMed ID: 32939265
[TBL] [Abstract][Full Text] [Related]
3. An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.
Cohen JA; Bomben R; Pozzo F; Tissino E; Härzschel A; Hartmann TN; Zucchetto A; Gattei V
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272636
[TBL] [Abstract][Full Text] [Related]
4. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
[TBL] [Abstract][Full Text] [Related]
6. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
International CLL-IPI working group
Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
[TBL] [Abstract][Full Text] [Related]
8. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
Nabhan C; Raca G; Wang YL
JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
[TBL] [Abstract][Full Text] [Related]
9. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
Rossi D; Gerber B; Stüssi G
Leuk Lymphoma; 2017 Jul; 58(7):1548-1560. PubMed ID: 27808579
[TBL] [Abstract][Full Text] [Related]
11. Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.
van der Straten L; Hengeveld PJ; Kater AP; Langerak AW; Levin MD
Front Oncol; 2021; 11():780085. PubMed ID: 34956898
[TBL] [Abstract][Full Text] [Related]
12. Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL.
Kittai AS; Lunning M; Danilov AV
Curr Hematol Malig Rep; 2019 Aug; 14(4):302-309. PubMed ID: 31049852
[TBL] [Abstract][Full Text] [Related]
13. Prognostication of chronic lymphocytic leukemia in the era of new agents.
Eichhorst B; Hallek M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):149-155. PubMed ID: 27913474
[TBL] [Abstract][Full Text] [Related]
14. Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages.
Suárez-Cabrera A; Fiallo-Suárez DV; Stuckey R; Uroz-de la Iglesia ML; Florido Y; Lemes-Castellano A; Perera-Álvarez MÁ; Luzardo-Henríquez H; de la Nuez H; Fernández-Caldas P; de la Iglesia S; Gómez-Casares MT; Bilbao-Sieyro C
Diagnostics (Basel); 2022 Jul; 12(8):. PubMed ID: 35892513
[TBL] [Abstract][Full Text] [Related]
15. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?
Rosenquist R; Cortese D; Bhoi S; Mansouri L; Gunnarsson R
Leuk Lymphoma; 2013 Nov; 54(11):2351-64. PubMed ID: 23480493
[TBL] [Abstract][Full Text] [Related]
16. Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.
Turcsanyi P; Kriegova E; Kudelka M; Radvansky M; Kruzova L; Urbanova R; Schneiderova P; Urbankova H; Papajik T
Leuk Res; 2019 Apr; 79():60-68. PubMed ID: 30852300
[TBL] [Abstract][Full Text] [Related]
17. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
18. Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients.
Chauzeix J; Laforêt MP; Deveza M; Crowther L; Marcellaud E; Derouault P; Lia AS; Boyer F; Bargues N; Olombel G; Jaccard A; Feuillard J; Gachard N; Rizzo D
Cancer Med; 2018 Jun; 7(6):2621-2628. PubMed ID: 29745034
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers.
Amaya-Chanaga CI; Rassenti LZ
Best Pract Res Clin Haematol; 2016 Mar; 29(1):79-89. PubMed ID: 27742074
[TBL] [Abstract][Full Text] [Related]
20. Precision Medicine Management of Chronic Lymphocytic Leukemia.
Moia R; Patriarca A; Schipani M; Ferri V; Favini C; Sagiraju S; Al Essa W; Gaidano G
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32164276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
